<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9025">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05706857</url>
  </required_header>
  <id_info>
    <org_study_id>22/720-EC_X</org_study_id>
    <nct_id>NCT05706857</nct_id>
  </id_info>
  <brief_title>Evaluation of the Clinical Impact of Ultra Fast-Track in Patients Undergoing Cardiac Surgery</brief_title>
  <acronym>CARDU-FAST</acronym>
  <official_title>Evaluation of the Clinical Impact of Ultra Fast-Track in Patients Undergoing Cardiac Surgery Versus Conventional Extubation (CARDU-FAST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital San Carlos, Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center randomized clinical trial. The main aim is to demonstrate the superiority at&#xD;
      the clinical level of the ultra fast-track programs versus conventional early postoperative&#xD;
      extubation in patients undergoing cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is aimed to compare clinical superiority of ultra fast-track versus conventional&#xD;
      early postoperative extubation in patients undergoing cardiac surgery in our center. The&#xD;
      estimated sample size is 382 patients. They will be randomized 1:1 to any of the two arms of&#xD;
      the study (ultra fast-track vs. fast-track). The randomization will be stratified according&#xD;
      the type of surgery performed. The period of recruitment will start in January 2023 and is&#xD;
      supposed to finish by December 2024 or earlier. The main outcomes of the study will be&#xD;
      measured 1 year after the procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 22, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Randomized 1:1. Stratified by type of surgery (CABG, Valvular, Aorta)</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>Double</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the effect of Ultra Fast-track</measure>
    <time_frame>1 year</time_frame>
    <description>Determine the effect of Ultra Fast-track on the occurrence of the composite outcome composed of all-cause mortality, respiratory complications (prolonged intubation over 24h, reintubation, or pneumonia) and AKIN-III (acute renal failure) in patients undergoing ultra fast-track and patients with conventional postoperative extubation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural resources conpsumption</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of operating room occupancy time (minutes), ICU stay and overall postoperative stay (days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the need for high flow nasal oxygen therapy or non-invasive ventilation for &gt;24h.</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the need for high flow nasal oxygen therapy or non-invasive ventilation for &gt;24h after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in major bleeding or life-threatening bleeding.</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the event of major bleeding or life-threatening bleeding (VARC 2 definition).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in neurological complication</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the incidence of neurological complication after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the incidence of acute myocardial infarction.</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the incidence of acute myocardial infarction after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the incidence of heart reoperation</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the reoperation rate after the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the incidence of infections rate.</measure>
    <time_frame>1 year</time_frame>
    <description>Comparison of the incidence of infection that requires intravenous antibiotic therapy, which causes an increase in hospital stay or engage patient's life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">382</enrollment>
  <condition>Cardiac Disease</condition>
  <condition>Surgery</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Ultra fast-track</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are extubated in the operating room after the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional extubation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are extubated in the intensive unit care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Ultra Fast-track</intervention_name>
    <description>Patients are extubated in the operating room</description>
    <arm_group_label>Conventional extubation</arm_group_label>
    <arm_group_label>Ultra fast-track</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years of age.&#xD;
&#xD;
          -  Patients with valvular, coronary or aortic heart disease with an indication for major&#xD;
             cardiac surgery.&#xD;
&#xD;
          -  The patient's desire to participate in the clinical trial verified by signing the&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy.&#xD;
&#xD;
          2. Emergent surgery or cardiorespiratory arrest.&#xD;
&#xD;
          3. Patient in preoperative cardiogenic shock, or in need of high-dose vasoactive support.&#xD;
&#xD;
          4. Aortic arch procedures.&#xD;
&#xD;
          5. Procedures in which hypothermia &lt; 28ÂºC of temperature is expected during the&#xD;
             intervention.&#xD;
&#xD;
          6. Minor cardiac surgery procedures.&#xD;
&#xD;
          7. Procedures with minimally invasive techniques without extracorporeal circulation&#xD;
             (Transcatheter aortic valve implantation, Transcatheter mitral valve implantation,&#xD;
             Minimally invasive mitral valve repair (TOP-Mini), Totally thoracoscopic MAZE&#xD;
             procedure, Minimally invasive direct coronary artery bypass grafting).&#xD;
&#xD;
          8. Implantation of circulatory assistance devices or ECMO (extracorporeal membrane&#xD;
             oxygenation).&#xD;
&#xD;
          9. Active endocarditis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lourdes Montero Cruces</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Carlos, Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lourdes Montero Cruces</last_name>
    <phone>616622432</phone>
    <email>lourdes.montero@salud.madrid.org</email>
  </overall_contact>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 20, 2023</study_first_submitted>
  <study_first_submitted_qc>January 30, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2023</study_first_posted>
  <last_update_submitted>January 30, 2023</last_update_submitted>
  <last_update_submitted_qc>January 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital San Carlos, Madrid</investigator_affiliation>
    <investigator_full_name>Lourdes Montero Cruces</investigator_full_name>
    <investigator_title>Cardiovascular Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

